MALVERN, Pa., May 23, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Chris Thatcher, President and Chief Executive Officer, will participate in the William Blair 39th Annual Growth Stock Conference on Wednesday, June 5, 2019, at the Loews Chicago Hotel in Chicago, Illinois. The Company is scheduled to present at the conference at 10 a.m. CT (11 a.m. ET) the same day.
A live audio webcast of the conference presentation will be available online at the Investor Relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.
About Neuronetics
Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at www.neuronetics.com.
Investor Contact:
Mark R. Klausner
Westwicke Partners
443-213-0501
ir@neuronetics.com
Media Contact:
Leanne Scott Brown
Vault Communications
610-455-2742
Lbrown@vaultcommunications.com
Neuronetics